Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $1,298,797.92 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 39,816 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $32.62, for a total value of $1,298,797.92. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $794,394.86. This represents a 62.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Wednesday, January 28th, Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $31.80, for a total transaction of $1,037,061.60.
• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $32.78, for a total transaction of $1,127,632.00.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.75, for a total transaction of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total transaction of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $31.12 on Friday. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $42.00. The business’s fifty day moving average price is $35.05 and its two-hundred day moving average price is $31.38. The company has a market capitalization of $3.53 billion, a P/E ratio of -15.18 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. On average, research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on NAMS shares. Royal Bank Of Canada increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. HC Wainwright started coverage on NewAmsterdam Pharma in a research note on Monday, October 20th. They set a “buy” rating and a $52.00 price target for the company. Stifel Nicolaus boosted their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Leerink Partners reaffirmed an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. State of New Jersey Common Pension Fund D purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $539,000. Moody Aldrich Partners LLC purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at $5,036,000. Simon Quick Advisors LLC acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $202,000. UBS Group AG grew its holdings in shares of NewAmsterdam Pharma by 17.0% during the fourth quarter. UBS Group AG now owns 899,442 shares of the company’s stock valued at $31,552,000 after buying an additional 130,922 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of NewAmsterdam Pharma by 34.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,477 shares of the company’s stock valued at $929,000 after buying an additional 6,735 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.